Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Revenue (2021 - 2024)

Solid Biosciences (SLDB) has disclosed Revenue for 4 consecutive years, with -$75000.0 as the latest value for Q4 2024.

  • Quarterly Revenue changed N/A to -$75000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$340000.0 through Dec 2024, down 180.99% year-over-year, with the annual reading at $203000.0 for FY2025, 159.71% up from the prior year.
  • Revenue hit -$75000.0 in Q4 2024 for Solid Biosciences, up from -$82000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $6.2 million in Q2 2022 to a low of -$121000.0 in Q1 2023.
  • Historically, Revenue has averaged $1.8 million across 4 years, with a median of $925000.0 in 2022.
  • Biggest five-year swings in Revenue: soared 71.65% in 2022 and later crashed 106.29% in 2023.
  • Year by year, Revenue stood at $3.5 million in 2021, then skyrocketed by 74.41% to $6.2 million in 2022, then crashed by 101.96% to -$121000.0 in 2023, then surged by 38.02% to -$75000.0 in 2024.
  • Business Quant data shows Revenue for SLDB at -$75000.0 in Q4 2024, -$82000.0 in Q3 2024, and -$88000.0 in Q2 2024.